Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Identifieur interne : 001017 ( Ncbi/Checkpoint ); précédent : 001016; suivant : 001018Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
Auteurs : François Viallet [France] ; Séverine Pitel ; Sylvie Lancrenon ; Olivier BlinSource :
- Current medical research and opinion [ 1473-4877 ] ; 2013.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Benzothiazoles (administration & dosage), Benzothiazoles (adverse effects), Double-Blind Method, Female, Gastrointestinal Diseases (chemically induced), Humans, Indans (administration & dosage), Indans (adverse effects), Male, Middle Aged, Monoamine Oxidase Inhibitors (administration & dosage), Monoamine Oxidase Inhibitors (adverse effects), Parkinson Disease (drug therapy), Sleep Wake Disorders (chemically induced), Time Factors.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Benzothiazoles, Indans, Monoamine Oxidase Inhibitors.
- chemical , adverse effects : Antiparkinson Agents, Benzothiazoles, Indans, Monoamine Oxidase Inhibitors.
- chemically induced : Gastrointestinal Diseases, Sleep Wake Disorders.
- drug therapy : Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Time Factors.
Abstract
Rasagiline is a second-generation, irreversible MAO-B inhibitor (MAOB-I) previously shown to be efficacious and well-tolerated compared to placebo in the treatment of early Parkinson's disease (PD). ACTOR (ACceptabilité TOlérance Rasagiline) was a 15-week, multi-center, randomized, double-blind study aimed to assess the safety and tolerability of rasagiline compared to the dopaminergic agonist pramipexole in the treatment of early PD.
DOI: 10.1185/03007995.2012.752351
PubMed: 23176073
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000788
- to stream PubMed, to step Curation: 000755
- to stream PubMed, to step Checkpoint: 000755
- to stream Ncbi, to step Merge: 001017
- to stream Ncbi, to step Curation: 001017
Links to Exploration step
pubmed:23176073Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.</title><author><name sortKey="Viallet, Francois" sort="Viallet, Francois" uniqKey="Viallet F" first="François" last="Viallet">François Viallet</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier du Pays d’Aix, Aix-en-Provence, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier du Pays d’Aix, Aix-en-Provence</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Aix-en-Provence</settlement></placeName></affiliation></author><author><name sortKey="Pitel, Severine" sort="Pitel, Severine" uniqKey="Pitel S" first="Séverine" last="Pitel">Séverine Pitel</name></author><author><name sortKey="Lancrenon, Sylvie" sort="Lancrenon, Sylvie" uniqKey="Lancrenon S" first="Sylvie" last="Lancrenon">Sylvie Lancrenon</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23176073</idno><idno type="pmid">23176073</idno><idno type="doi">10.1185/03007995.2012.752351</idno><idno type="wicri:Area/PubMed/Corpus">000788</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000788</idno><idno type="wicri:Area/PubMed/Curation">000755</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000755</idno><idno type="wicri:Area/PubMed/Checkpoint">000755</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000755</idno><idno type="wicri:Area/Ncbi/Merge">001017</idno><idno type="wicri:Area/Ncbi/Curation">001017</idno><idno type="wicri:Area/Ncbi/Checkpoint">001017</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.</title><author><name sortKey="Viallet, Francois" sort="Viallet, Francois" uniqKey="Viallet F" first="François" last="Viallet">François Viallet</name><affiliation wicri:level="3"><nlm:affiliation>Centre Hospitalier du Pays d’Aix, Aix-en-Provence, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Centre Hospitalier du Pays d’Aix, Aix-en-Provence</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Aix-en-Provence</settlement></placeName></affiliation></author><author><name sortKey="Pitel, Severine" sort="Pitel, Severine" uniqKey="Pitel S" first="Séverine" last="Pitel">Séverine Pitel</name></author><author><name sortKey="Lancrenon, Sylvie" sort="Lancrenon, Sylvie" uniqKey="Lancrenon S" first="Sylvie" last="Lancrenon">Sylvie Lancrenon</name></author><author><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name></author></analytic><series><title level="j">Current medical research and opinion</title><idno type="eISSN">1473-4877</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Benzothiazoles (administration & dosage)</term><term>Benzothiazoles (adverse effects)</term><term>Double-Blind Method</term><term>Female</term><term>Gastrointestinal Diseases (chemically induced)</term><term>Humans</term><term>Indans (administration & dosage)</term><term>Indans (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (administration & dosage)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Sleep Wake Disorders (chemically induced)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzothiazoles</term><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Gastrointestinal Diseases</term><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Rasagiline is a second-generation, irreversible MAO-B inhibitor (MAOB-I) previously shown to be efficacious and well-tolerated compared to placebo in the treatment of early Parkinson's disease (PD). ACTOR (ACceptabilité TOlérance Rasagiline) was a 15-week, multi-center, randomized, double-blind study aimed to assess the safety and tolerability of rasagiline compared to the dopaminergic agonist pramipexole in the treatment of early PD.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Provence-Alpes-Côte d'Azur</li></region><settlement><li>Aix-en-Provence</li></settlement></list><tree><noCountry><name sortKey="Blin, Olivier" sort="Blin, Olivier" uniqKey="Blin O" first="Olivier" last="Blin">Olivier Blin</name><name sortKey="Lancrenon, Sylvie" sort="Lancrenon, Sylvie" uniqKey="Lancrenon S" first="Sylvie" last="Lancrenon">Sylvie Lancrenon</name><name sortKey="Pitel, Severine" sort="Pitel, Severine" uniqKey="Pitel S" first="Séverine" last="Pitel">Séverine Pitel</name></noCountry><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Viallet, Francois" sort="Viallet, Francois" uniqKey="Viallet F" first="François" last="Viallet">François Viallet</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001017 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001017 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:23176073
|texte= Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:23176073" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |